巴曲酶联合右旋糖苷40对短暂性脑缺血发作的疗效观察

Effect of batroxobin and dextran 40 injection in the treatment of transient ischemic attack

目的评估巴曲酶联合复方右旋糖苷40治疗短暂性脑缺血发作的临床疗效及安全性。方法选取短暂性脑缺血发作患者180例,随机分为对照组(90例)及治疗组(90例),观察治疗后短暂性脑缺血发作控制的时间及发生率,并监测治疗组治疗前后凝血时间、出血时间、凝血酶原时间和血小板计数。结果2组治疗后10 d内控制率分别为78.89%和91.11%,组间比较有显著性差异(P<0.05)。治疗组治疗前后凝血时间、出血时间、凝血酶原时间和血小板计数无明显变化;2组均未发生严重不良反应。结论巴曲酶联合复方右旋糖苷40治疗短暂性脑缺血发作患者疗效显著,且无严重不良反应。

Objective To evaluate the efficacy and security of batroxobin and dextran 40 injection in transient ischemic attack.Methods 180 patients of transient ischemic attack were selected,which were randomly divided into two groups.The efficacy was observed and the change of BT,CT,PT and PLT were investigated before and after treatment.Results The control rate of the two groups was 78.89%and 91.11%within 10 days after treatment,The effective rate was significantly different(P<0.05).There were no significant changes in BT,CT,PT and PLT after treatment in the treatment group,and no serious adverse reactions in the two groups.Conclusion Batroxobin and dextran 40 injection were useful for transient ischemic attack.It suggests that them can be used to patients with transient ischemic attack in clinic.